Axinn Successfully Represents Alvogen Before FTC
November 3, 2015
Axinn successfully represented Alvogen before the Federal Trade Commission in connection with Alvogen’s approval to buy the divestiture products in the proposed Mylan/Perrigo transaction. Mylan’s bid for Perrigo is valued at $25 billion, and Alvogen will acquire seven separate pharmaceutical products as a result of the FTC-mandated and approved divestiture. Alvogen was also approved to acquire the divestiture products in Pfizer/Hospira earlier this year. The FTC’s Mylan press release can be found here.
The Axinn team based in Washington, DC consisted of partner Michael Keeley, assisted by associate Kenina Lee.
To subscribe to our publications, click here.
Featured Insights
Featured Insights
GCR Live: Law Leaders Europe 2025
Speaking Engagement
Antitrust
AHLA Annual Meeting 2025
Speaking Engagement
Antitrust
SABA North America Annual Conference 2025
Speaking Engagement
Antitrust
Navigating Compliance: How the 2025 Hart-Scott-Rodino Updates Are Impacting Businesses
Webinar
Antitrust
Volunteer Lawyers for the Arts – Champions of the Arts Awards and Gala 2025
Sponsorship
Antitrust
NJSBA Annual Meeting and Convention 2025
Speaking Engagement
Intellectual Property
Cost-Effective and Efficient IP Litigation Strategies – Making Paragraph IV Litigation Work for You
Webinar
Intellectual Property
Hartford HealthCare Black and Red Gala 2025
Sponsorship
Antitrust
Informa CompLaw Antitrust West Coast Conference 2025
Speaking Engagement
Antitrust
Recent Decision Shows the Heavy Burden of Actual Malice in Defamation Suits
Axinn Viewpoints
Litigation & Trials